University of Pennsylvania researchers used TriNetX health records from June 2022 to January 2025 to compare adults with type 2 diabetes who started semaglutide, tirzepatide, or an SGLT2 inhibitor, reporting in Diabetes, Obesity and Metabolism. Over roughly 10 to 12 months of follow-up, hospitalizations or emergency visits for alcohol use disorder occurred at 2.42 versus 4.53 per 1,000 person-years for semaglutide versus SGLT2 inhibitors (hazard ratio 0.54) and 2.34 versus 3.98 for tirzepatide (0.61), with no difference between the two GLP-1 drugs (0.98). The study is observational.
Altimmune Inc. (NASDAQ: ALT) presented Thursday September 10, 2026 at the Wells Fargo 21st Annual Healthcare Conference in Boston, outlining a three-front development plan for pemvidutide (an investigational once-weekly GLP-1/glucagon dual agonist peptide with FDA Breakthrough Therapy Designation for MASH). PERFORMA is the Phase 3 MASH trial with a 5-year duration and 52-week accelerated-approval look; readout is expected in 2029. RECLAIM is the Phase 2 alcohol use disorder trial reporting consistent reductions in heavy drinking days, a 2.2-level drop in WHO Risk Drinking Level, improvement in zero-heavy-drinking-days, and lower phosphatidylethanol (PEth) alcohol-consumption biomarker levels versus placebo. RESTORE is the Phase 2 alcohol-related liver disease trial that has completed enrollment and uses FibroScan liver stiffness as the primary endpoint with 12-month readout and 6-month interim. Altimmune reported $519 million in cash as of June 30, 2026, funding the MASH Phase 3 program through the 2029 readout. Pemvidutide is one of three glucagon-containing peptide candidates in late-stage MASH development alongside Boehringer-Zealand's survodutide and Lilly's retatrutide.